Interleukin 1 (IL1) – Pipeline Review, H1 2018

Global Markets Direct’s, ‘Interleukin 1 (IL1) – Pipeline Review, H1 2018’, provides in depth analysis on Interleukin 1 (IL1) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

Additionally, the report provides an overview of key players involved in Interleukin 1 (IL1) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas under Cardiovascular, Immunology, Metabolic Disorders, Oncology, Dermatology, Musculoskeletal Disorders, Ear Nose Throat Disorders, Gastrointestinal, Genetic Disorders, Central Nervous System and Genito Urinary System And Sex Hormones development targeting Interleukin 1 (IL1).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

– The report provides a snapshot of the global therapeutic landscape for Interleukin 1 (IL1)

– The report reviews Interleukin 1 (IL1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved in Interleukin 1 (IL1) targeted therapeutics and enlists all their major and minor projects

– The report assesses Interleukin 1 (IL1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news and deals related to Interleukin 1 (IL1) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Interleukin 1 (IL1)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Interleukin 1 (IL1) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Apexigen Inc

Exicure Inc

Immune Response BioPharma Inc

Moderna Therapeutics Inc

Novartis AG

Omnitura Therapeutics Inc

Opsona Therapeutics Ltd

Optimum Therapeutics LLC

Peptinov SAS

R Pharm

Regeneron Pharmaceuticals Inc

Spherium Biomed SL

Swedish Orphan Biovitrum AB

XBiotech Inc

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Interleukin 1 (IL1) Overview 9

Interleukin 1 (IL1) Therapeutics Development 10

Products under Development by Stage of Development 10

Products under Development by Therapy Area 11

Products under Development by Indication 12

Products under Development by Companies 15

Products under Development by Universities/Institutes 20

Interleukin 1 (IL1) Therapeutics Assessment 22

Assessment by Mechanism of Action 22

Assessment by Route of Administration 24

Assessment by Molecule Type 26

Interleukin 1 (IL1) Companies Involved in Therapeutics Development 28

Apexigen Inc 28

Exicure Inc 28

Immune Response BioPharma Inc 28

Moderna Therapeutics Inc 29

Novartis AG 29

Omnitura Therapeutics Inc 30

Opsona Therapeutics Ltd 30

Optimum Therapeutics LLC 31

Peptinov SAS 31

R Pharm 32

Regeneron Pharmaceuticals Inc 32

Spherium Biomed SL 32

Swedish Orphan Biovitrum AB 33

XBiotech Inc 33

Interleukin 1 (IL1) Drug Profiles 35

AC-203 Drug Profile 35

Product Description 35

Mechanism Of Action 35

R&D Progress 35

Antisense Oligonucleotide to Inhibit IL-1 Beta for Epidermolysis Bullosa Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

APX-002 Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

canakinumab Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

diacerein Drug Profile 49

Product Description 49

Mechanism Of Action 49

R&D Progress 49

diacerein CR Drug Profile 51

Product Description 51

Mechanism Of Action 51

R&D Progress 51

IR-1000 Drug Profile 52

Product Description 52

Mechanism Of Action 52

R&D Progress 52

IR-1002 Drug Profile 53

Product Description 53

Mechanism Of Action 53

R&D Progress 53

IR-888 Drug Profile 54

Product Description 54

Mechanism Of Action 54

R&D Progress 54

LH-026 Drug Profile 55

Product Description 55

Mechanism Of Action 55

R&D Progress 55

melittin Drug Profile 56

Product Description 56

Mechanism Of Action 56

R&D Progress 56

Monoclonal Antibodies to Inhibit IL-1a for Myocardial Infarction and Atherosclerosis Drug Profile 57

Product Description 57

Mechanism Of Action 57

R&D Progress 57

mRNA-2752 Drug Profile 58

Product Description 58

Mechanism Of Action 58

R&D Progress 58

OMN-54 Drug Profile 59

Product Description 59

Mechanism Of Action 59

R&D Progress 59

PPV-01 Drug Profile 61

Product Description 61

Mechanism Of Action 61

R&D Progress 61

rilonacept Drug Profile 62

Product Description 62

Mechanism Of Action 62

R&D Progress 62

RPH-104 Drug Profile 65

Product Description 65

Mechanism Of Action 65

R&D Progress 65

Small Molecules to Inhibit Interleukin 1 Beta for Muckle-Wells Syndrome, Neonatal Onset Multisystem Inflammatory Disease and Gouty Arthritis Drug Profile 66

Product Description 66

Mechanism Of Action 66

R&D Progress 66

SOBI-006 Drug Profile 67

Product Description 67

Mechanism Of Action 67

R&D Progress 67

SP-15008 Drug Profile 68

Product Description 68

Mechanism Of Action 68

R&D Progress 68

suramin hexasodium Drug Profile 69

Product Description 69

Mechanism Of Action 69

R&D Progress 69

Xilonix Drug Profile 71

Product Description 71

Mechanism Of Action 71

R&D Progress 71

Interleukin 1 (IL1) Dormant Products 84

Interleukin 1 (IL1) Discontinued Products 90

Interleukin 1 (IL1) Product Development Milestones 93

Featured News & Press Releases 93

Apr 16, 2018: XBiotech Announces Upcoming Phase 2 Clinical Studies in Dermatology 93

Mar 12, 2018: Canakinumab Doesn’t Prevent Prediabetes from Progressing to Diabetes 93

Feb 26, 2018: TWi Biotechnology Announced Regulatory Clearance to Begin Phase 2 Proof-of-Concept Clinical trial of AC-203 for treatment of Inherited Epidermolysis Bullosa 94

Jan 26, 2018: XBiotech Announces Presentation of Data from Phase 2 Study Evaluating MABp1 for the Treatment of Hidradenitis Suppurativa 95

Jan 19, 2018: XBiotech Announces Presentation of Phase 2 Open Label Extension Study Data Evaluating MABp1 for the Treatment of Hidradenitis Suppurativa 96

Jan 15, 2018: Castle Creek Pharmaceuticals Announces Data Validating First Investigator's Global Assessment Scale for Epidermolysis Bullosa Simplex Clinical Research 96

Jan 03, 2018: Castle Creek Pharmaceuticals to Participate in 5th Annual Dermatology Summit 97

Dec 04, 2017: XBiotech Announces Publication of Phase II Data from Hidradenitis Suppurativa Phase II Study in The Journal of Investigative Dermatology 98

Nov 14, 2017: XBiotech Announces Presentation of Novel Findings for MABp1 in the Prevention of Coronary Thrombosis at the American Heart Association Scientific Sessions 98

Nov 13, 2017: Novartis canakinumab (ACZ885) reduced cardiovascular risk by 25% in subgroup of CANTOS Phase III trial participants 99

Nov 13, 2017: Response after Single Treatment with Canakinumab Predicts Which Patients Will Benefit Most 100

Nov 03, 2017: XBiotech’s MABp1 to be Featured in Oral Presentation at the American Heart Association Scientific Sessions 102

Nov 01, 2017: TWi Biotechnology Presents Positive Results from AC-201 CR Phase 2 Proof-of-Concept Study in Gout Patients in 2017 ACR/ARPH Annual Meeting 102

Oct 27, 2017: Castle Creek Pharmaceuticals Receives Partners in Progress Award from debra of America 103

Oct 18, 2017: XBiotech Announces First Patient in Study Evaluating MABp1 in Combination with Onivyde and 5-fluorouracil/folinic acid for the Treatment of Pancreatic Cancer 103

Appendix 105

Methodology 105

Coverage 105

Secondary Research 105

Primary Research 105

Expert Panel Validation 105

Contact Us 105

Disclaimer 106

List of Tables

List of Tables

Number of Products under Development by Stage of Development, H1 2018 10

Number of Products under Development by Therapy Areas, H1 2018 11

Number of Products under Development by Indications, H1 2018 13

Number of Products under Development by Indications, H1 2018 (Contd..1), H1 2018 14

Number of Products under Development by Companies, H1 2018 15

Products under Development by Companies, H1 2018 16

Products under Development by Companies, H1 2018 (Contd..1), H1 2018 17

Products under Development by Companies, H1 2018 (Contd..2), H1 2018 18

Products under Development by Companies, H1 2018 (Contd..3), H1 2018 19

Number of Products under Investigation by Universities/Institutes, H1 2018 20

Products under Investigation by Universities/Institutes, H1 2018 21

Number of Products by Stage and Mechanism of Actions, H1 2018 23

Number of Products by Stage and Route of Administration, H1 2018 25

Number of Products by Stage and Molecule Type, H1 2018 27

Pipeline by Apexigen Inc, H1 2018 28

Pipeline by Exicure Inc, H1 2018 28

Pipeline by Immune Response BioPharma Inc, H1 2018 29

Pipeline by Moderna Therapeutics Inc, H1 2018 29

Pipeline by Novartis AG, H1 2018 30

Pipeline by Omnitura Therapeutics Inc, H1 2018 30

Pipeline by Opsona Therapeutics Ltd, H1 2018 31

Pipeline by Optimum Therapeutics LLC, H1 2018 31

Pipeline by Peptinov SAS, H1 2018 31

Pipeline by R Pharm, H1 2018 32

Pipeline by Regeneron Pharmaceuticals Inc, H1 2018 32

Pipeline by Spherium Biomed SL, H1 2018 33

Pipeline by Swedish Orphan Biovitrum AB, H1 2018 33

Pipeline by XBiotech Inc, H1 2018 34

Dormant Products, H1 2018 84

Dormant Products, H1 2018 (Contd..1), H1 2018 85

Dormant Products, H1 2018 (Contd..2), H1 2018 86

Dormant Products, H1 2018 (Contd..3), H1 2018 87

Dormant Products, H1 2018 (Contd..4), H1 2018 88

Dormant Products, H1 2018 (Contd..5), H1 2018 89

Discontinued Products, H1 2018 90

Discontinued Products, H1 2018 (Contd..1), H1 2018 91

Discontinued Products, H1 2018 (Contd..2), H1 2018 92

List of Figures

List of Figures

Number of Products under Development by Stage of Development, H1 2018 10

Number of Products under Development by Therapy Areas, H1 2018 11

Number of Products under Development by Top 10 Indications, H1 2018 12

Number of Products by Mechanism of Actions, H1 2018 22

Number of Products by Stage and Mechanism of Actions, H1 2018 22

Number of Products by Routes of Administration, H1 2018 24

Number of Products by Stage and Routes of Administration, H1 2018 24

Number of Products by Molecule Types, H1 2018 26

Number of Products by Stage and Molecule Types, H1 2018 26

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports